Stock Research Monitor: IMDZ, IMUC, and LXRX
LONDON, UK / ACCESSWIRE / May 11, 2018 / If you want a free Stock Review on LJPC sign up now at www.wallstequities.com/registration. On Thursday, the NASDAQ Composite ended the day at 7,404.97, up 0.89%; the Dow Jones Industrial Average edged 0.80% higher, to finish at 24,739.53; and the S&P 500 closed at 2,723.07, marginally gaining 0.94%. Gains were broad based as eight out of nine sectors finished the trading session in green. WallStEquities.com has initiated research reports on the following Biotechnology stocks: Immune Design Corp. (NASDAQ: IMDZ), ImmunoCellular Therapeutics Ltd (NYSE AMER: IMUC), La Jolla Pharmaceutical Co. (NASDAQ: LJPC), and Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX). All you have to do is sign up today for this free limited time offer by clicking the link below.
Seattle, Washington headquartered Immune Design Corp.'s stock finished Thursday's session flat at $3.75 with a total trading volume of 115,529 shares. The stock has gained 15.38% over the past three months. The Company's shares are trading above their 50-day moving average by 6.31%. Moreover, shares of Immune Design, which engages in the research and development of in vivo treatments for cancer, have a Relative Strength Index (RSI) of 53.80. Get the full research report on IMDZ for free by clicking below at:
Shares in Westlake Village, California-based ImmunoCellular Therapeutics Ltd declined 3.53%, ending yesterday's session at $0.27 with a total trading volume of 618,054 shares. The stock has gained 16.30% in the past month and 18.88% in the previous three months. The Company's shares are trading above their 50-day moving average by 2.81%. Moreover, shares of the Company, which develops immune-based therapies for the treatment of various cancers, have an RSI of 51.50. Gain free access to the research report on IMUC at:
La Jolla Pharmaceutical
On Thursday, San Diego, California headquartered La Jolla Pharmaceutical Co.'s stock saw a drop of 2.69%, to close the day at $31.16. A total volume of 667,717 shares was traded, which was higher than their three months average volume of 545.07 thousand shares. The Company's shares have advanced 17.14% over the last twelve months. The stock is trading above its 50-day moving average by 2.34%. Additionally, shares of La Jolla Pharma, which focuses on the discovery, development, and commercialization of therapeutics for life-threatening diseases, have an RSI of 52.64. Register for your free report coverage on LJPC at:
The Woodlands, Texas headquartered Shares in Lexicon Pharmaceuticals Inc. ended the day 0.11% lower at $9.31. A total volume of 452,533 shares was traded. The stock has gained 12.30% in the last month. The Company's shares are trading above their 50-day moving average by 10.49%. Furthermore, shares of Lexicon Pharma, which focuses on the development and commercialization of pharmaceutical products for the treatment of human diseases, have an RSI of 64.96. Get the free research report on LXRX at:
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: 21 32 044 483
Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: Wall St. Equities